These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1679365)

  • 1. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.
    Alexander GM; Brainard DL; Gordon SW; Hichens M; Grothusen JR; Schwartzman RJ
    Brain Res; 1991 May; 547(2):181-9. PubMed ID: 1679365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
    Alexander GM; Schwartzman RJ; Grothusen JR; Brainard L; Gordon SW
    Brain Res; 1993 Oct; 625(2):276-82. PubMed ID: 8275309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
    Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
    Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
    Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
    Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
    Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
    Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
    Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Clarke CE; Boyce S; Sambrook MA; Stahl SM; Crossman AR
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):35-8. PubMed ID: 2907097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
    Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
    Rouillard C; Bédard PJ; Di Paolo T
    Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
    Luquin MR; Laguna J; Obeso JA
    Ann Neurol; 1992 May; 31(5):551-4. PubMed ID: 1350718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis).
    Graham WC; Clarke CE; Boyce S; Sambrook MA; Crossman AR; Woodruff GN
    Brain Res; 1990 Apr; 514(1):103-10. PubMed ID: 2192772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
    Calon F; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Neurochem Int; 1999 Jul; 35(1):81-91. PubMed ID: 10403433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys.
    Herrero MT; Augood SJ; Asensi H; Hirsch EC; Agid Y; Obeso JA; Emson PC
    Brain Res Mol Brain Res; 1996 Nov; 42(1):149-55. PubMed ID: 8915594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.